With increased understanding of the extreme variability of normal and pathological physiology, the pharmaceutical industry has started to realize the importance of personalizing treatment regimes in order to obtain maximized treatment effects. This is also true for cancer treatment.
A ”companion diagnostic” is a diagnostic product that gives essential information that can be extrapolated on the efficiency and safety of a corresponding therapeutic product. This is relevant for e.g. immunotherapies, but also for nanomedical products where the prerequisites for positive treatment outcomes, such as degree of EPR-effect, varies greatly between individuals and tumors.
Spago Nanomedical’s contrast agent for MRI, SpagoPix has the potential to be used as a companion diagnostic to select patients with high probability of benefiting from therapeutic treatment with Tumorad and other nanomedical therapeutics.